PulmoBREATHE® and PulmoLOR® in Treatment of Patients with Respiratory Diseases

Gogunskaya I.V., D. of M. S., T.V.  Smagina, C. of M. S., I.S. Zaritskaya, C. of M. S., Center of allergic respiratory diseases PI "Institute of Otolaryngology named after A.I. Kolomiychenko NAMS of Ukraine ", Kiev

The complex products  PulmoBREATHE® and PulmoLOR® (MoviHealth, Switzerland) contain ambroxol  hydrochloride (30 and 60 mg respectively) and are prescribed  to patients who need correction of rheological properties administered to patients in need of correction of the rheological properties of the tracheobronchial secretions and secretions of the nasal cavity and paranasal sinuses (such as acute respiratory infections). However, availability of the second active ingredient in each of the specified medicinal product demands the differentiated approach to their appointment.

For the purpose of differentiation of the combined products PulmoLOR® and PulmoBREATHE® it is necessary to consider factors such as history, course of the disease, presence of complications, comorbidities and other diseases and conditions.

Thus, the combination of ambroxol and acetylcysteine (PulmoBREATHE®) and loratadine and ambroxol (PulmoLOR®) can be used in complex treatment of patients with various diseases of respiratory system, upper respiratory tract as allergic and non-allergic genesis. Complex products PulmoBREATHE® and  PulmoLOR® of the company MoviHealth (Switzerland) have a lot of positive feedbacks in the clinical practice of doctors of different specialties.